Product Image
More sustainable than new
$228.85$549.70Save 58%

Product Details

Manufacturer
SKU
HPA030049ICC
Shipped From
Sweden

About this product

Anti-CDCA2

by Atlas Antibodies · SKU HPA030049ICC

Overview

The Anti-CDCA2 antibody (HPA030049) is a rabbit Triple A Polyclonal reagent directed against human CDCA2, a chromatin-associated factor implicated in cell cycle progression and protein phosphatase regulation. The immunogen corresponds to a recombinant sequence enriched in regulatory and basic motifs. Validated exclusively for immunocytochemistry, it enables intracellular localisation of CDCA2 in cultured cells.

Highlights

  • Rabbit Triple A Polyclonal antibody recognising human CDCA2
  • Validated only for immunocytochemistry (ICC)
  • Recombinant antigen fragment containing regulatory domains
  • Formulated in PBS with glycerol and preservative

At-a-glance

Antigen
CDCA2 (cell division cycle associated 2)
Antibody type
Triple A Polyclonал
Host species
Rabbit
Isotype
IgG
Validation
ICC only
Immunogen sequence
IKCERKDDFLGAAEGKLQCNRLMPNSQKDCHCLGDVLIENTKESKSQSEDLGRKPMESSSVVSCRDRKDRRRSMCYSDGRSLHLEKNGNHTPSS
Buffer composition
40% glycerol and PBS (pH 7.2). 0.02% sodium azide is added as preservative.
Condition
New

Applications

This antibody enables ICC-based localisation of CDCA2, supporting studies of chromatin-associated regulators, mitotic signalling, and cell cycle–dependent protein distribution.

Sustainability

By rehoming surplus lab products, this listing supports waste reduction and resource efficiency.

Related Products

What Our Clients Say

Supporting innovation at leading research companies

RNAnalytics

RNAnalytics

Leading The Way In Gene Therapy Analytics

As a startup focused on developing analytical toolkits for LNP characterization, RNAnalytics operates under tight budget constraints while striving to maintain a fully stocked lab with high-quality materials. Sustainability is also a core pillar of our operations, pushing us to make environmentally conscious decisions wherever possible....